B. R. Kusuma

发表

Cruentaren A Binds F1F0 ATP Synthase To Modulate the Hsp90 Protein Folding Machinery

J. Hall, B. Blagg, B. R. Kusuma, 2014, ACS chemical biology.

Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors.

B. Blagg, A. Duerfeldt, B. R. Kusuma, 2011, Bioorganic & medicinal chemistry letters.

Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents.

B. Blagg, J. Holzbeierlein, R. Rajewski, 2011, Journal of medicinal chemistry.

Targeting the heat shock protein 90 dimer with dimeric inhibitors.

B. Blagg, J. Holzbeierlein, Huiping Zhao, 2011, Journal of medicinal chemistry.

Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors.

B. Blagg, J. Holzbeierlein, Douglas Brown, 2014, Bioorganic & medicinal chemistry.

Cytotoxic sugar analogues of an optimized novobiocin scaffold

Huiping Zhao, Brian S. J. Blagg, B. Blagg, 2010 .

Synthesis and Evaluation of Noviose Replacements on Novobiocin that Manifest Anti-proliferative Activity.

B. Blagg, Huiping Zhao, B. R. Kusuma, 2010, ACS medicinal chemistry letters.

Synthesis and Evaluation of Noviose Replacements on Novobiocin That Manifest Antiproliferative Activity

B. Blagg, Huiping Zhao, B. R. Kusuma, 2010 .

Synthesis and evaluation of novologues as C-terminal Hsp90 inhibitors with cytoprotective activity against sensory neuron glucotoxicity.

R. Dobrowsky, B. Blagg, Liangyu Zhang, 2012, Journal of medicinal chemistry.

Synthesis of cruentaren A.

B. Blagg, B. R. Kusuma, Gary E. L. Brandt, 2012, Organic letters.

Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors.

B. Blagg, J. Holzbeierlein, R. Matts, 2013, Assay and drug development technologies.

Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents.

B. Blagg, J. Holzbeierlein, R. Rajewski, 2011, Journal of Medicinal Chemistry.